Alzheimer’s disease with an early debut
https://doi.org/10.21518/2079-701X-2019-1-10-16
Abstract
The article reviews a clinical case of Alzheimer’s disease (AD) with early onset. This case study shows current approaches to the diagnosis of this form of AD and the management of this group of patients. It is reasonable to use Acathinol memantin in patients with early onset of AD. The drug is characterized by a minimal number of side effects and a limited spectrum of contraindications.
Keywords
About the Authors
N. N. KoberskayaRussian Federation
Candidate of Medical Sciences, Assistant of the Department of Nervous Diseases and Neurosurgery of the Medical Faculty of the Federal State Autonomous Educational Institution of Higher Education «First Moscow State Medical University named after I.M. Sechenov» of the Ministry of Health of the Russian Federation (Sechenov University)
N. A. Kovalchuk
Russian Federation
Postgraduate Student of the Department of Nervous Diseases and Neurosurgery of the Medical Faculty of the Federal State Autonomous Educational Institution of Higher Education «First Moscow State Medical University named after I.M. Sechenov» of the Ministry of Health of the Russian Federation (Sechenov University)
References
1. Terry R.D., Davies P. Dementia of the Alzheimer type. Annu Rev Neurosci. 1980;3:77–95.
2. Zhu X.C., Tan L., Wang H.F., et al. Rate of early onset Alzheimer’s disease: a systematic review and meta-analysis. Annals of translational medicine. 2015;3(3):38.
3. Lambert M.A., Bickel H., Prince M., et al. Estimating the burden of early onset dementia; systematic review of disease prevalence. Eur J Neurol. 2014;21(4):563–569.
4. van Vliet D., de Vugt M.E., Bakker C., et al. Time to diagnosis in young-onset dementia as compared with late-onset dementia. Psychol Med. 2013;43(2):423–432.
5. Stanley K., Walker Z. Do patients with young onset Alzheimer’s disease deteriorate faster than those with late onset Alzheimer’s disease? A review of the literature. International psychogeriatrics. IPA. 2014; 26(12):1945–1953;
6. Smits L.L., Pijnenburg Y.A., van der Vlies A.E., et al. Early onset APOE E4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology. 2015.
7. Palasi A., Gutierrez-Iglesias B., Alegret M., et al. Differentiated clinical presentation of early and late-onset Alzheimer’s disease: is 65 years of age providing a reliable threshold? J Neurol. 2015;262(5):1238–1246.
8. Joubert S., Gour N., Guedj E., et al. Early-onset and late-onset Alzheimer’s disease are associated with distinct patterns of memory impairment. Cortex. 2016;74:217–232.
9. Koedam E.L., Lauffer V., van der Vlies A.E., van der Flier W.M., Scheltens P., Pijnenburg Y.A. Early-versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis. 2010;19(4):1401–1408.
10. Ossenkoppele R., Pijnenburg Y.A., Perry D.C., et al. The behavioural/dysexecutive variant of Alzheimer’s disease: clinical, neuroimaging and pathological features. Brain. 2015;138(Pt 9):2732–2749.
11. Tsuno N., Homma A. What is the association between depression and Alzheimer’s disease? Expert Rev Neurother. 2009 Nov;9(11):1667-76.
12. Cho H., Jeon S., Kang S.J., et al. Longitudinal changes of cortical thickness in early-versus late-onset Alzheimer’s disease. Neurobiology of aging. 2013;34(7): 1921–e9.
13. Migliaccio R., Agosta F., Possin K.L., et al. Mapping the Progression of Atrophy in Early and Late- Onset Alzheimer’s Disease. J Alzheimers Dis. 2015; 46:351–364.
14. Chiaravalloti A., Koch G., Toniolo S., et al. Comparison between Early-Onset and Late-Onset Alzheimer’s Disease Patients with Amnestic Presentation: CSF and (18) F-FDG PET Study. Dementia and geriatric cognitive disorders extra. 2016;6(1):108–119.
15. Kaiser N.C., Melrose R.J., Liu C., et al. Neuropsychological and neuroimaging markers in early versus late-onset Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2012;27(7):520–529.
16. Palasi A., Gutierrez-Iglesias B., Alegret M., et al. Differentiated clinical presentation of early and late-onset Alzheimer’s disease: is 65 years of age providing a reliable threshold? J Neurol. 2015; 262:1238–1246.
17. Murray M.E., Graff-Radford N.R., Ross O.A., Petersen R.C., Duara R., Dickson D.W. Neuropathologically defined subtypes of Alzheimer’s disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10(9):785–796.
18. Jarmolowicz A.I., Chen H.Y., Panegyres P.K. The patterns of inheritance in early-onset dementia: Alzheimer’s disease and frontotemporal dementia. Am J Alzheimers Dis Other Demen. 2015;30(3):299–306.
19. Muller U., Winter P., Graeber M.B. A presenilin 1 mutation in the first case of Alzheimer’s disease. Lancet Neurol. 2013;12(2):129–130.
20. De Luca V., Orfei M.D., Gaudenzi S., Caltagirone C., Spalletta G. Inverse effect of the APOE epsilon4 allele in late- and early-onset Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 2016 Oct 29;266(7):599-606. Epub 2015 Dec 29.
21. Nicolas G., Charbonnier C., Wallon D., et al. SORL1 rare variants: a major risk factor for familial early-onset Alzheimer’s disease. Molecular psychiatry. 2016;21(6):831–836.
22. Koberskaya N.N. Alzheimer’s disease: new diagnostic criteria and therapeutic aspects depending on the stage of the disease. Medical Council [Meditsinskiy Sovet], 2017;10:18-24. (in Russ).
23. Cummings J., Aisen P., DuBois B. Drug development in Alzheimer’s disease: the path to 2025. Cummings et al. Alzheimer’s Research & Therapy. 2016;8:39.
24. Schmidt R., Ropele S., Ebenbauer B. et al. Memantine effects on brain volume, glucose metabolism and cognition in AD patients. Eur J Neurology. 2007;14(1): 2526.
25. Koberskaya N.N. Clinical, diagnostic and therapeutic aspects of moderate cognitive amnestic-type disorders. Medical Council [Meditsinskiy Sovet]. 2015;5:40-45. (in Russ).
26. Peskind E.R., Potkin S.G., Pomara N. et al. Memantine treatment in mild to moderate Alzheimer’s disease. Am J Geriatr Psychiatry. 2006;14:704–15.
27. Porsteinsson A., Grossberg G., Mintzer J., Olin J. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83–89.
28. Reisberg B., Doody R., Stoffler A., Schmitt F. et al. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003; 348:1333–41.
29. Reisberg B., Doody R., Stoffler A. et al. A 24-week open-label extension study of memantine in moderate to severe Alzheimer’s disease. Arch Neurol. 2006;63:49–54.
30. Tocco M., Resnick E.M., Graham S. et al. Cognitive effects of memantine in moderate to severe Alzheimer’s disease: a responder analysis. Eur J Neurology. 2007;14(1):1098.
31. Winblad B., Jones R., Wirth Y. et al. Memantine in moderate to severe Alzheimer’s disease: meta-analysis of randomized clinical trials. Dement Geriatr Cogn Disord. 2007;24:20–7.
32. Ito K. et al. Memantine inhibits β-amyloid aggregation and disassembles preformed β-amyloid aggregates. Biochemical and Biophysical Research Communications. 2017;493(1):158-163.
33. Parfenov V.A., Zakharov V.V., Preobrazhenskaya I.S. Cognitive disorders. M: Remedium, 2014. (in Russ).
34. Parfenov V.A. Early diagnosis and treatment of Alzheimer’s disease. Medical Council [Meditsinskiy Sovet]. 2015;5:28-33. (in Russ).
Review
For citations:
Koberskaya NN, Kovalchuk NA. Alzheimer’s disease with an early debut. Meditsinskiy sovet = Medical Council. 2019;(1):10-16. (In Russ.) https://doi.org/10.21518/2079-701X-2019-1-10-16